VILTEPSO: AN FDA-APPROVED TREATMENT FOR PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) AMENABLE TO EXON 53 SKIPPING
This is a pre-recorded webinar with CureDuchenne, NS Pharma and guest speaker Dr. Mathula Thangarajh.
• Clinical evidence to support early initiation of DMD treatment
• The role of exon skipping in the treatment of DMD
• The efficacy of VILTEPSO for the treatment of DMD
• The safety and tolerability profile of VILTEPSO
Recorded Tuesday, March 7, 2023